BDNF and major depressive disorder: Our results showed that higher doses of GTS treatment (50 and 25 mg kg−1 d−1) normalized the downregulated hippocampal mRNA and protein levels of BDNF as well as decreasing the activation of CREB in the corticosterone-induced mouse depression model.